Z-ligustilide Inhibits Rotavirus VP6 Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rotavirus infections lack effective specific clinical drugs and vaccines, with limited strain coverage due to rotavirus variability and diversity.
Innovation Solution
Z-ligustilide, a phthalide compound, is used to inhibit rotavirus biosynthesis by targeting the gene expression of the structural protein VP6, effectively preventing and controlling rotavirus infections at a concentration of 70-85 μM, formulated into anti-rotavirus agents in various pharmaceutical forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Z-ligustilide is used to inhibit rotavirus biosynthesis, then the anti-rotavirus effect is improved, but the concentration range is narrow (70-85 μM)
Solution Approach 1:
The patent identifies a specific concentration range (70-85 μM, preferably 80 μM) where Z-ligustilide effectively inhibits rotavirus biosynthesis without causing cell toxicity. This parameter optimization resolves the contradiction by defining the precise conditions under which the compound achieves maximum therapeutic effect with minimal side effects.
2Reliability
If Z-ligustilide concentration is increased to improve anti-rotavirus effect, then virus inhibition is enhanced, but cell toxicity increases
Solution Approach 1:
The patent establishes a narrow therapeutic window (70-85 μM) where Z-ligustilide effectively inhibits rotavirus biosynthesis while avoiding cell toxicity. Concentrations below this range are insufficient for virus inhibition, while concentrations above this range cause harmful effects to host cells.
3Reliability
If Z-ligustilide targets VP6 gene expression to inhibit rotavirus, then specific anti-rotavirus activity is improved, but the mechanism is limited to structural protein inhibition
Solution Approach 1:
The patent identifies and targets a specific viral component (VP6 structural protein gene expression) as the mechanism of action for Z-ligustilide. By extracting and targeting this specific viral element, the compound achieves effective anti-rotavirus activity through inhibition of viral biosynthesis rather than through multiple mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Z-ligustilide demonstrates no toxicity to cells at 60-95 μM and achieves significant inhibition of rotavirus biosynthesis at 70-85 μM, specifically by reducing VP6 expression, providing an effective means to prevent and control rotavirus infections without direct killing or adsorption.
Implementation Method 1
Z-ligustilide further inhibits rotavirus biosynthesis by inhibiting the gene expression of the rotavirus VP6
Data Source
AI summary
The present invention discloses an application of Z-ligustilide in resisting rotaviruses, and relates to the technical field of medicines. Z-ligustilide has no drug toxicity to cells at 60-95 μM and can effectively inhibit rotavirus biosynthesis at 70-85 μM. Z-ligustilide plays a role in resisting rotavirus biosynthesis by inhibiting structural protein VP6, and has no effect of adsorbing and directly killing rotaviruses, which provides a new way for resisting rotaviruses.